Triclabendazole

Generic Name
Triclabendazole
Brand Names
Egaten
Drug Type
Small Molecule
Chemical Formula
C14H9Cl3N2OS
CAS Number
68786-66-3
Unique Ingredient Identifier
4784C8E03O
Background

Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. Fascioliasis is a parasitic infection often caused by the helminth, Fasciola hepatica, which is also known as “the common liver fluke” or “the sheep liver fluke” or by Fasciola gigantica, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food.

Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.

This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.

Indication

This drug is indicated for the treatment of fascioliasis in patients aged 6 years old and above.

Associated Conditions
Fascioliasis
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath